Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Abbott Buys Remaining Stake In Mavik And Tarka From Aventis For $300 Mil.

This article was originally published in The Pink Sheet Daily

Executive Summary

Abbott originally obtained marketing rights for the two cardiovascular drugs under a 1991 licensing agreement. Abbott expects peak sales to reach $700 mil. (versus $200 mil.-plus in 2003). The sale is not related to the Sanofi merger, Aventis says, but rather is part of an effort to divest underperforming brands.
Advertisement
Advertisement

Related Content

Topics

Advertisement
UsernamePublicRestriction

Register

PS059839

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel